Heparin-induced thrombocytopenia

Hamostaseologie

Volumn 30, Issue 1, 2010, Pages 17-28

  Greinacher, A ^a   Althaus, K ^a   Krauel, K ^a   Selleng, S ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Anti coagulants; Heparin; Heparin induced thrombocytopenia; Immunology; Pathogenesis; Platelets

Indexed keywords

ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; COUMARIN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; IMMUNOGLOBULIN G; LEPIRUDIN; PHENPROCOUMON; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; BLEEDING; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HOST RESISTANCE; HUMAN; IMMUNOASSAY; IMMUNOBIOLOGY; IMMUNOLOGY; LABORATORY TEST; PARTICLE GEL IMMUNOASSAY; PATHOGENESIS; RENAL REPLACEMENT THERAPY; REVIEW; THROMBOCYTE; THROMBOSIS;

EID: 77949311486     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617144     Document Type: Review

References (91)

1. Alberio L, Kimmerle S, Baumann A et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 2003; 114: 528-536.
2. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol 2008; 20: 149-157.
3. Althaus K, Strobel U, Fuerll B, Greinacher A. Improving the capability of the anti-PF4/heparin ELIA to rule out platelet activating PF4/heparin antibodies. J Thromb Haemost 2009, 7: 275.
4. Amiral J, Bridey F, Dreyfus M et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96.
5. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
6. Arepally G, Ponzc M, Cines DB. Immune vascular injury in heparin-induced thrombocytopenia. In: Heparin-induced thrombocytopenia. Informa Healthcare 2007; 209-225.
7. Asmis LM, Segal JB, Plantinga LC et al. Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost 2008; 100: 498-504.
8. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009; 7: 911-918.
9. Bartholomew JR, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis 2005; 19: 183-188.
10. Bauer TL, Arepally G, Konkle BA et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95: 1242-1246.
11. Beiderlinden M, Treschan TA, Gorlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007; 41: 749-754.
12. Bennett-Guerrero E, Slaughter TF, White WD et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005; 130: 1567-1572.
13. Chong BH, Magnani HN. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Heparin-induced thrombocytopenia. Informa Healthcare 2007; 295-318.
14. Chong BH, Murray B, Berndt MC et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994; 83: 1535-1541.
15. Crowther MA, Cook DJ, Meade MO et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005; 20: 348-353.
16. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparininduced thrombocytopenia. Ann Pharmacother 2006; 40: 1383-1387.
17. Eichler P, Raschke R, Lubenow N et al. The new ID-heparin/ PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002; 116: 887-891.
18. Everett BM, Yeh R, Foo SY et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 2007; 83: 592-597.
19. Francis JL, Drexler A, Duncan MK et al. Prospective evaluation of laboratory teests for the diagnosis of heparin-induced thrombocytopenia. Blood 2006; 108: 312a.
20. Francis, JL, Drexler A, Gwyn G. Successful use of bivalirudin in the treatment of patients suspected, or at risk of, heparin-induced thrombocytopenia Blood 2004; 104: 105b.
21. Greinacher A, Warkentin TE. Risk of heparin-induced thrombocytopenia in patients receiving thrombois prophylaxis. Exp Rev Hematol 2008; 1: 75-85.
22. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl 1): 9-12.
23. Greinacher A, Alban S, Omer-Adam MA et al. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008; 122: 211-220.
24. Greinacher A, Farner B, Kroll H et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-135.
25. Greinacher A, Fuerll B, Zinke H et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood 2009; 114: 1250-1253.
26. Greinacher A, Gopinadhan M, Gunther JU et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006; 26: 2386-2393.
27. Greinacher A, Juhl D, Strobel U et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5: 1666-1673.
28. Greinacher A, Kohlmann T, Strobel U et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 4970-4976.
29. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-736.
30. Greinacher A, Pötzsch B, Amiral J et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-251.
31. Greinacher A, Zinn S, Wizemann, Birk UW. Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis. Lancet 1996; 348: 764.
32. Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem 1976; 251: 4273-4282.
33. Hinz P, Lubenow N, Wessel A et al. Thrombosis prophylaxis in trauma surgery units in Germany: A survey. Unfallchirurg 2009; Epub ahead of print.
34. Hutchison CA, Dasgupta I. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 2007; 22: 1680-1684.
35. Janatpour KA, Gosselin RC, Dager WE et al. Usefulness of optical density values from heparin-platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia. Am J Clin Pathol 2007; 127: 429-433.
36. Juhl D, Eichler P, Lubenow N et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420-426.
37. Kelton JG, Sheridan D, Santos A et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-930.
38. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006; 26: 452-460.
39. Kress DC, Aronson S, McDonald ML et al. Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes. Ann Thorac Surg 2007; 83: 1737-1743.
40. Lewis BE, Hursting MJ. Argatroban therapy in heparin-induced thrombocytopenia. In: Heparin-induced thrombocytopenia. Informa Healthcare. 2007; 379-408.
41. Lindhoff-Last E, Eichler P, Stein M et al. A prospective study on the incidence and clinical relevance of heparin- induced antibodies in patients after vascular surgery. Thromb Res 2000; 97: 387-393.
42. Lindhoff-Last E, Piechottka GP, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 2000; 100: 55-60.
43. Lo GK, Juhl D, Warkentin TE, Sigouin CS et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759-765.
44. Lubenow N, Eichler P, Albrecht D et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature. Thromb Res 2000; 100: 115-125.
45. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3: 2428-2436.
46. Lubenow N, Kempf R, Eichner A et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122: 37-42.
47. Martin-Toutain I, Piette JC, Diemert MC et al. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. Lupus 2007; 16: 79-83.
48. Matsuo T, Kobayashi H, Matsuo M et al. Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis. Pathophysiol Haemost Thromb 2006; 35: 445-450.
49. Matsuo T, Kusano H, Wanaka K et al. Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Hemost 2007; 13: 182-187.
50. Mattioli AV, Bonetti L, Zennaro M et al. Heparin/ PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. Am Heart J 2009; 157: 589-595.
51. Nader ND, Khadra WZ, Reich NT et al. Blood product use in cardiac revascularization: comparison of on- and off-pump techniques. Ann Thorac Surg 1999; 68: 1640-1643.
52. Pauzner R, Greinacher A, Selleng K et al. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009; 7: 1070-1074.
53. Pouplard C, Gueret P, Fouassier M et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 5: 1373-1379.
54. Pouplard C, Iochmann S, Renard B et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97: 3300-3302.
55. Pouplard C, May MA, Iochmann S et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-2536.
56. Pouplard C, May MA, Regina S et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128: 837-841.
57. Rauova L, Zhai L, Kowalska MA et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006; 107: 2346-2353.
58. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99: 779-781.
59. Schenk S, El Banayosy A, Morshuis M et al. IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb Haemost 2007; 5: 235-241.
60. Selleng S, Malowsky B, Bagemühl J et al. Incidence and clinical significance of anti-platelet factor 4/heparin antibodies determined before cardiac surgery Hämostaseologie 2009; 29: A64.
61. Selleng S, Malowsky B, Strobel U et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia even when antibody tests are positive. J Thromb Haemost 2009; Epub ahead of print.
62. Selleng S, Selleng K, Wollert HG, et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost 2008; 6: 428-435.
63. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
64. Sikara MP, Routsias JG, Samiotaki M et al. β2 glycoprotein I (β2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood 2010; 115: 713-723.
65. Spectre G, Kalish Y, Schliamser L, Varon D. Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication? Am J Hematol 2008; 83: 420-423.
66. Suvarna S, Rauova L, McCracken EK et al. PF4/heparin complexes are T cell-dependent antigens. Blood 2005; 106: 929-931.
67. Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 1997; 12: 2750-2755.
68. Trossaert M, Gaillard A, Commin PL et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998; 101: 653-655.
69. Wanaka K, Matsuo T, Matsuo M et al. Re-exposure to heparin in uremic patients requiring hemodialyisis with heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7.
70. Warkentin TE, Jay RM, Makris M, Kelton JG. Platelet-activating anti-platelet factor 4/polyanion antibodies without receding heparin therapy: a transient autoimmune disorder resembling heparin-induced thrombocytopenia ("spontaneous HIT") Blood, 2006, 108: 311a-312a.
71. Warkentin TE, Cook RJ. Impact of laboratory testing for heparin-induced antibodies: using Bayes-'rule to prevent overdiagnosis. J Clin Chem Lab Med 2010; in press.
72. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998; 35: 9-16.
73. Warkentin TE. Drug-induced immune-mediated thrombocytopenia - from purpura to thrombosis. N Engl J Med 2007; 356: 891-893
74. Warkentin TE. Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies-distinguishing "signal" from "noise". Thromb Haemost 2008; 100: 523-524.
75. Warkentin TE, Crowther MA. When is HIT really HIT? Ann Thorac Surg 2007; 83: 21-23.
76. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Informa Healthcare USA 2007; 227-260.
77. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
78. th ed). Chest 2008; 133: 340S-380S.
79. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.
80. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
81. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008; 121: 632-636.
82. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2655.
83. Warkentin TE, Sheppard JA, Horsewood P et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-1708.
84. Warkentin TE, Sheppard JA, Moore JC et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146: 341-346.
85. Warkentin TE, Sheppard JI, Moore JC et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 1304-1312.
86. Warkentin TE, Sheppard JI, Raschke R, Greinacher A. Performance characteristics of a rapid assay for anti-PF4/heparin antibodies: the particle immunofiltration assay. J Thromb Haemost 2007; 5: 2308-2310.
87. Warkentin T, Sheppard JA, Moore JC et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963-4966.
88. Weiss BM, Shumway NM, Howard RS et al. Optical density values correlate with the clinical probability of heparin induced thrombocytopenia. J Thromb Thrombolysis 2008; 26: 243-247.
89. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/ platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008; 100: 678-684.
90. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001; 293: 251-253.
91. Zwicker JI, Uhl L, Huang WY et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2: 2133-2137.